Effects of sodium–glucose cotransporter 2 inhibitors on cardiovascular and renal outcomes in people with diabetes and advanced chronic kidney disease

Lo, Hao-Yun
DOI: https://doi.org/10.1007/s00125-024-06257-7
IF: 8.2
2024-08-31
Diabetologia
Abstract:Although the benefits of sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in chronic kidney disease (CKD) are well established, the effects of these therapeutic agents in patients with advanced CKD are less certain. We hypothesised that the continued use of these drugs, even when renal function deteriorates to stage 4 CKD or worse, is safe and associated with improved cardiorenal survival.
endocrinology & metabolism
What problem does this paper attempt to address?